Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet | PCD Pharma Manufacturer & Supplier India | Trumac Healthcare
Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet
WHO-GMP Manufacturer & PCD Pharma Franchise Supplier in India
Form: Tablet
Class: Anti-leukotriene + H1-antihistamine + mucolytic-bronchodilator
✓ Pan-India Monopoly PCD
✓ 1 Brand Options
Pricing, brochure & monopoly territory within 24 hrs.
Our Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet Brand Options (1 option)
Trumac Healthcare manufactures and supplies the following Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet brands for PCD pharma distribution. Click any brand to view full specifications and packaging.
Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet is manufactured under WHO-GMP-certified conditions by Trumac Healthcare and supplied for PCD/Propaganda-cum-Distribution pharma franchise on monopoly basis across India. Whether you are a PCD distributor, stockist or retail chemist, our Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) formulation comes with full quality assurance, regulatory documentation and reliable pan-India despatch.
Therapeutic Indications
- Allergic rhinitis with concomitant asthma
- Chronic bronchitis with allergic component
- Asthma maintenance with allergic triggers
- Exercise-induced bronchoconstriction
Mechanism of Action
Montelukast blocks CysLT1 receptors on bronchial smooth muscle and inflammatory cells, reducing leukotriene-mediated bronchoconstriction, mucus secretion and eosinophil recruitment. Fexofenadine selectively antagonises peripheral H1 receptors to control histamine-driven sneezing, rhinorrhoea and itch without crossing the blood-brain barrier. Acebrophylline is a salt of ambroxol and theophylline-acetate: ambroxol hydrolyses mucopolysaccharide fibres and stimulates surfactant; theophylline component inhibits phosphodiesterase, raising intracellular cAMP for bronchodilation.
Dosage & Administration
- Adults: 1 tablet once daily, preferably at night
- Swallow whole — do not crush or chew the SR tablet
- Take with or without food
- Use only as advised by the physician
Side Effects
- Headache
- Mild GI upset
- Nausea
- Palpitations occasionally
- Sleep disturbance (with theophylline component)
Contraindications
- Hypersensitivity to any component
- Acute severe asthma attack (does not treat acute bronchospasm)
- Active peptic ulcer disease
- Severe cardiac arrhythmia
- Uncontrolled hyperthyroidism
Storage
Store below 30 °C in a dry place, protected from light and moisture.
PCD Pharma Franchise for Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet
- ✓ WHO-GMP certified manufacturing facility
- ✓ Pan-India monopoly distribution rights available
- ✓ Multiple pack sizes: 10 x 10 (Alu-Alu)
- ✓ Trade-friendly PTR / PTS margins
- ✓ Free promotional material on request
- ✓ Full DCGI documentation and quality certificates supplied
Trumac Healthcare offers 1 brand option for Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet — each available in different pack sizes with trade-friendly margins. View the brand-specific pages below for detailed specifications, MRPs and packaging options.
For PCD franchise opportunities, monopoly distribution rights, or third-party contract manufacturing of Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet, contact our business development team. WhatsApp +91 9041677932 or email info@trumachealthcare.net.
Frequently Asked Questions
Who is the manufacturer of Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet?
Trumac Healthcare is a WHO-GMP certified manufacturer of Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet in India. We supply our own brand range (see brand options above) and also offer third-party contract manufacturing for PCD distributors.
Is Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet available for PCD pharma franchise on monopoly basis?
Yes. We offer Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet for PCD/Propaganda-cum-Distribution pharma franchise on monopoly basis across all districts of India. Contact our business development team for pricing and territory availability.
What pack sizes are available for Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet?
Available pack sizes include: 10 x 10 (Alu-Alu).
What is the MRP / trade price for Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet?
MRPs range from ₹2585 to ₹2585 across our brand variants. Trade-friendly PTR/PTS margins available on request — WhatsApp +91 9041677932 for current rates.
How do I place an order or franchise enquiry?
WhatsApp +91 9041677932 or email info@trumachealthcare.net with your enquiry. Our team will revert within 24 hours with full pricing, brochure and franchise terms.
Ready to start your PCD franchise for Montelukast (10 mg) + Fexofenadine (120 mg) + Acebrophylline (200 mg) (As Sustained Release) Tablet?